Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study. Issue 4 (August 2015)

• Record Type: Journal Article
• Authors: Buchacz, Kate; Wiegand, Ryan; Armon, Carl; Chmiel, Joan S.; Wood, Kathleen; Brooks, John T.; Palella Jr., Frank J.
• Is Part Of: HIV clinical trials. Volume 16:Issue 4(2015)
• Page Start: 139
• Page End: 146
• Publication Date: 2015-08
• Subjects: HIV Infections -- Chemotherapy -- Periodicals; AIDS (Disease) -- Chemotherapy -- Periodicals; HIV Infections -- Research -- Periodicals; AIDS (Disease) -- Research -- Periodicals; 616.979206105
• DOI: 10.1179/1528433614Z.0000000019
• Languages: German
• ISSNs: 1528-4336

Abstract

<abstract> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <sec> <title>Objectives:</title> <p>Raltegravir (RAL)-containing antiretroviral therapy (ART) produced better immunologic and virologic responses than optimized background ART in clinical trials of heavily ART-experienced patients, but few data exist on long-term outcomes in routine HIV care.</p> </sec> <sec> <title>Methods:</title> <p>We studied ART-experienced HIV outpatient study (HOPS) participants seen at 10 US HIV-specialty clinics during 2007–2011.We identified patients who started (baseline date) either continuous ≥ 30 days of RAL-containing or RAL-sparing ART, and used propensity score (PS) matching methods to account for baseline clinical and demographic differences. We used Kaplan–Meier methods and log-rank tests for the matched subsets to evaluate probability of death, achieving HIV RNA < 50 copies/ml, and CD4 cell count (CD4) increase of ≥ 50 cells mm<sup>− 3</sup> during follow-up.</p> </sec> <sec> <title>Results:</title> <p>Among 784 RAL-exposed and 1062 RAL-unexposed patients, 472 from each group were matched by PS. At baseline, the 472 RAL-exposed patients (mean nadir CD4, 205 cells mm<sup>− 3</sup>; mean baseline CD4, 460 cells mm<sup>− 3</sup>; HIV RNA < 50 copies ml<sup>− 1</sup> in 61%; mean years on prescribed ART, 7.5) were similar to RAL unexposed. During a mean follow-up of over 3 years, mortality rates and immunologic and virologic trajectories did not differ between the two groups. Among patients with detectable baseline HIV RNA levels, 76% of RAL-exposed and 63% of RAL-unexposed achieved HIV RNA < 50 copies ml<sup>− 1</sup> (<italic>P</italic> = 0.51); 69 and 58%, respectively, achieved a CD4 increase ≥ 50 cells mm<sup>− 3</sup> (<italic>P</italic> = 0.70).</p> </sec> <sec> <title>Discussion:</title> <p>In our large cohort of US ART-experienced patients with a wide spectrum of clinical history, similar outcomes were observed when prescribed RAL containing versus other contemporary ART.</p> </sec> </abstract>